We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
-1.99%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$97.8M
AUM Growth
-$2.67M
Cap. Flow
+$5.27M
Cap. Flow %
5.39%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$6.51M

Top Sells

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$1.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$29.7M 30.41%
3,959,440
– –
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$26.4M 26.98%
273,077
– –
VERO
3
DELISTED
Venus Concept
VERO
$22.2M 22.75%
1,442
– –
VBIV
4
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$9.42M 9.63%
89,701
– –
EPIX
5
DELISTED
ESSA Pharma
EPIX
$6.37M 6.52%
1,668,561
+1,562,500
+1,473% +$6.51M
ATXS
6
DELISTED
Astria Therapeutics
ATXS
$3.63M 3.72%
33,470
-12,405
-27% -$1.24M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q1 2018 Portfolio in Review

As of Q1 2018, Clarus Ventures held 6 positions worth $97.8M, down 2.7% from $100M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures deployed $5.27M of net new capital in Q1 2018, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Astria Therapeutics, an estimated $1.24M trimmed.

  • Clarus Ventures added most to ESSA Pharma in Q1 2018, an estimated $6.51M increase.
  • Clarus Ventures's biggest Q1 2018 reduction was Astria Therapeutics, cutting an estimated $1.24M.
  • Clarus Ventures's ten largest holdings make up 100% of its $97.8M portfolio in Q1 2018.
  • Clarus Ventures opened 0 new positions and closed 0 in Q1 2018.
  • Clarus Ventures's portfolio value fell 2.7% quarter-over-quarter to $97.8M.

Based on Clarus Ventures's 13F filing for Q1 2018, filed 25 Apr 2018.